<DOC>
	<DOCNO>NCT00748345</DOCNO>
	<brief_summary>Drug pharmacokinetics antimicrobial agent significantly alter burn patient . Additionally , burn patient population exhibit wide inter- intrapatient variation drug handling . Several investigation carry burn patient treat e.g . fluconazole show requirement increase daily dose comparison healthy volunteer . However , pharmacokinetic data available caspofungin burn population . The aim investigation investigate pharmacokinetics caspofungin burn patient single usual dose ( 70 mg i.v . ) , order determine optimal dose population .</brief_summary>
	<brief_title>Pharmacokinetics Caspofungin Burn Patients</brief_title>
	<detailed_description>The aim investigation investigate pharmacokinetics caspofungin burn patient single usual dose ( 70 mg i.v. ) . Blood sample draw administration 0.25 , 0.5,1 1.5 , 3 , 6 , 12 , 24 , 48 , 72 , 96 120 hour administration . Caspofungin plasma concentration measure liquid-chromatography spectrometry mass tandem.The primary end-points : - area curve caspofungin plasma concentration 24 hour - mean peak level trough concentration ( 24 hour dose ) The secondary end-points : - mean total clearance - mean distribution volume These parameter compare usually observe non burn patient . The optimal dose burn patient dose achieve exposure similar non burn patient .</detailed_description>
	<mesh_term>Caspofungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<criteria>18 60 year old burn surface : 2060 % total body surface area delay injury time : 815 day lack fungal infection delay hospitalization : &gt; 5 day write informed consent last biological picture 24 hour inclusion survival inferior 5 day surgical intervention plan next five day follow inclusion moderate severe hepatic impairment accord Child Plug B &gt; 9 pregnancy allergy caspofungin excipients ( saccharose , mannitol frozen acetic acid ) patient already include study concomitant administration CYP450 inducer : rifampicin , efavirenz , phenobarbital , phenytoin , carbamazepine withdrawal consent event ( first 48 hour follow administration ) susceptible modify pharmacokinetic parameter Investigator decision social security insurance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Caspofungin ,</keyword>
	<keyword>burn patient ,</keyword>
	<keyword>pharmacokinetics ,</keyword>
	<keyword>optimal dose ,</keyword>
	<keyword>antifungal treatment</keyword>
</DOC>